2026
conference-abstract
OpenAlex
Nazli Dizman, Yufan Qiu, Ehsan Irajizad, Satabdi Saha et autres
9575 Background: Multiple studies have now linked high fiber diet (HFD) and outcomes with ICBs, however, the clinical actionability and mechanistic basis of this association remain incompletely defined. We investigated whether microbiome-derived metabolites may function as potentially actionable mediators of this interaction. …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Elizabeth M. Burton, Krysta McVay, Denai Milton, Rodabe Navroze Amaria et autres
TPS9603 Background: Approved immune checkpoint blockade (ICB) agents for the treatment (tx) advanced, unresectable metastatic melanoma (MM) include NIVO (anti-PD1) alone or in combination with IPI (anti-CTLA-4) or RELA (anti-LAG3) and have transformed outcomes for patients with this disease. While doublet combinations …
us, ae
(code pays fourni par la source)
2026
article
OpenAlex
Thomas Hendrix Beckham, Stephanie O. Dudzinski, Michael K. Rooney, Christina Abi Faraj et autres
BACKGROUND: Historically, patients with ≥5 brain metastases (BM) were considered borderline or poor candidates for stereotactic radiosurgery (SRS). With increased survival and expanded treatment options for BM in the modern era, paradigms of BM management warrant reevaluation. Our objective was to determine …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Rodabe Navroze Amaria, Scott Kopetz, Maria Pia Morelli, George R. Blumenschein et autres
TPS2675 Background: The effectiveness and durability of TIL therapy may be limited by the immunosuppressive tumor microenvironment and baseline functionality of transferred T cells. Through KSQ Therapeutics’ CRISPR 2 platform, a novel method for screening optimal combinatorial targets for enhancing T cell …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Rodabe Navroze Amaria, Adi Diab, Hussein Abdul-Hassan Tawbi, Isabella Claudia Glitza et autres
9519 Background: Non-engineered TIL cell therapy is approved for ICI-resistant advanced melanoma, but requires co-administration of toxic high-dose IL2. OBX-115 engineered TIL express mbIL15 under pharmacologic regulation using the FDA-approved small-molecule drug acetazolamide (ACZ), abrogating the need for IL2. We present data …
us
(code pays fourni par la source)
2025
article
OpenAlex
Isabella Claudia Glitza, Suzanne M. Phillips, Ida John, Roland L. Bassett et autres
TPS9592 Background: Pts with LMD face dismal prognosis, with median overall survival (OS) measured in months. We previously reported the safety and efficacy data from an open label, single arm and center phase I/IB trial for MM pts with LMD, using IT/IV …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Florentia Dimitriou, Ashish V. Damania, Priyadharsini Nagarajan, Sabitha Prabhakaran et autres
9561 Background: MM is a rare melanoma subtype with distinct biology and low response rates to ICIs. We seek to prospectively profile a cohort of MM patients to determine the interplay of gut, mucosal and tumor microbiome and modifiable risk factors on …
us
(code pays fourni par la source)
2025
article
OpenAlex
Elizabeth M. Burton, Tara Marie Davidson, Krysta McVay, Denái R. Milton et autres
TPS9593 Background: NIVO (anti-PD1) alone or in combination with IPI (anti-CTLA-4) or RELA (anti-LAG3) are approved immune checkpoint blockade (ICB) agents for the treatment (tx) of patients (pts) with advanced, unresectable metastatic melanoma. Doublet combinations induce higher rates of durable disease control …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
J.S. Wefel, Hussein Abdul-Hassan Tawbi, Erik P. Sulman, Catherine M. Sullaway et autres
Abstract BACKGROUND Digital approaches to measuring and monitoring cognitive function (CF) are of interest as screening measures to enhance clinical care and clinical research. Validity related evidence for such measures is required prior to adopting these in practice and trials. Four investigator-initiated …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Eliane Aoun, Samantha H. Batman, Andrew Donghyun Kim, Gary B. Chisholm et autres
30 Background: Melanoma is the most prevalent cancer during pregnancy, representing 31% of all gestational cancers, with its incidence rates rising globally. Pregnancy-associated melanoma (PAM) presents unique challenges in diagnosis and management due to maternal physiological and hormonal changes, as well as …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Thomas Hendrix Beckham, Stephanie O. Dudzinski, Melisa Pasli, Subha Perni et autres
2026 Background: Stereotactic radiosurgery (SRS) is an ablative modality for focal treatment of brain metastases (BM) and is standard of care for limited BM. Suitability for SRS has historically been linked to number of BM, with up to 4 BM considered amenable …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Priya Kumthekar, Margaret A. Schwartz, Seema Nagpal, Isabella Claudia Glitza et autres
2031 Background: Leptomeningeal carcinomatosis (LC) represents an area of largely unmet clinical need, and intrathecal (IT) drug delivery is often used as treatment (tx). In addition, LC can lead to hydrocephalus, sometimes also during IT treatment . Intracranial pressure (ICP) changes might …
us
(code pays fourni par la source)